Comparing the current results to its competitors, Zymeworks Inc reported Revenue decrease in the 2 quarter 2026 year on year by -90.58 %, despite the revenue increase by the most of its competitors of 10.42 %, recorded in the same quarter.
Zymeworks Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical industry, which is characterized by rapid technological advancements and a focus on proprietary products. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Its product candidates compete with existing and future therapies. In its healthcare asset aggregation strategy, the company competes with other companies, funds, and investment vehicles that aggregate royalties or provide alternative financing to biotechnology companies. Some competitors may have advantages such as lower cost of capital or greater access to capital, enabling them to acquire assets targeted by the company.
May 22, 2025
Paving the Path in Oncology: Zymeworks Sets the Stage for Medical Breakthroughs at Premier Global Conferences In an inspiring move set to influence the oncology landscape significantly, Zymeworks Inc. (Nasdaq: ZYME) is gearing up to highlight its innovative strides in cancer treatment at the most anticipated global medical conferences of the year. Headquartered in Vancouver, British Columbia, this clinical-stage biotechnology company is poised to showcase a commanding array of presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Society of Medical Oncology (ESMO) Gynaecological Cancers Congress. This marks a pivotal moment for Zymeworks as it continues to unveil ...
November 5, 2024
Zymeworks Inc. a leading biotechnology firm focused on innovative biotherapeutics, has recently made significant strides in the development of ZW191, a novel folate receptor (FR)-targeted topoisomerase I inhibitor antibody-drug conjugate (ADC). With the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), ZW191 is poised to enter clinical evaluation, targeting advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers (NSCLC). This article discusses the implications of ZW191 in cancer therapy, highlights the ongoing Phase 1 clinical trial, and summarizes the preclinical advancements presented at the American Association for C...
August 22, 2024
Zymeworks Inc. Poised for Strategic Engagement at Prominent Investor Conferences Vancouver, British Columbia, August 22, 2024 - Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company at the frontier of developing innovative, multifunctional biotherapeutics, today disclosed its planned participation in a series of high-profile investor conferences. This engagement aligns with Zymeworks’ commitment to advancing the standard of care for challenging and intractable diseases through its diverse therapeutic pipeline.Zymeworks robust portfolio features cutting-edge biotherapeutics designed to address myriad complex diseases for which treatment options remain limited or ineffective. The companyâ€...
Pmv Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing precision therapies for cancer patients. They employ a collaborative business model that combines deep scientific expertise, strategic partnerships, and advanced technology to identify and target specific genetic alterations in cancer cells. By leveraging these insights, Pmv Pharmaceuticals aims to create innovative treatments that can improve patient outcomes and address unmet medical needs in oncology.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Nexien Biopharma Inc operates as a biotechnology company focused on the development and commercialization of innovative therapies for various medical conditions. They aim to use their expertise in biopharmaceutical research to bring novel treatments to market, improving patient outcomes and meeting unmet medical needs.
Sources:
Zymeworks Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zymeworks Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
